Unosi

• Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs (2014-06)

  B. Godman, R. Malmstrom, E. Digene, S. Jayathissa, S. McTaggart, T. Cars, S. Alvarez-Madrazo, C. Baumgartel, A. Brzezinska, A. Bucsics, S. Campbell, I. Eriksson, A. Finlayson, J. Furst, K. Garuoliene, I. Gutierrez-Ibarluzea, K. Hviding, H. Herholz, R. Joppi, R. Joppi, M. Kalaba, O. Laius, K. Malinowska, H. Pedersen, V. Marković Peković, J. Piessnegger, G. Selke, C. Sermet, S. Spillane, D. Tomek, L. Vončina, V. Vlahović-Palčevski, J. Wale, M. Wladysiuk, M. van Woerkom, C. Zara, L. Gustafsson, Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs, Frontiers in Pharmacology, Vol. 5, pp. 1 - 11, Jun, 2014

• Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs (2013-05)

  R. Malmstrom, E. Digene, C. Baumgartel, M. Bennie, I. Bishop, A. Brzezinska, S. Campbell, A. Ferrario, A. Finlayson, J. Furst, K. Garuoliene, M. Gomes, I. Gutierrez-Ibarluzea, A. Haycox, K. Hviding, H. Herholz, M. Hoffman, S. Jan, J. Jones, R. Joppi, M. Kalaba, C. Kvalheim, O. Laius, I. Langner, J. Lonsdale, S. Loov, K. Malinowska, L. McCullagh, K. Paterson, V. Marković Peković, A. Martin, J. Piessnegger, G. Selke, C. Sermet, S. Simoens, C. Tulnay, D. Tomek, L. Vončina, V. Vlahović-Palčevski, J. Wale, M. Wilcock, M. Wladysiuk, M. van Woerkom, C. Zara, L. Gustafsson, Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs, Frontiers in Pharmacology, Vol. 4, pp. 1 - 31, May, 2013

• Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future (2016-07)

  W. de Bruyn, C. Ibanez, H. Pedersen, A. Akan, P. Vella Bonanno, L. Sović-Brkičić, A. Bucsics, G. Dedet, J. Eriksen, J. Fadare, J. Furst, G. Gallego, I. Godoi, A. Guerra Junior, H. Gursoz, S. Jan, J. Jones, R. Joppi, S. Kerman, O. Laius, N. Madzikwa, E. Magnusson, M. Maticic, V. Marković Peković, A. Massele, O. Ogunleye, A. O'Leary, J. Piessnegger, C. Sermet, S. Simoens, C. Tiroyakgosi, I. Truter, M. Thyberg, K. Tomek, M. Wladysiuk, S. Vandoros, E. Vural, C. Zara, Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future, Frontiers in Pharmacology, Vol. 7, pp. 1 - 18, Jul, 2016

• Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways (2016-09)

  M. Ermisch, A. Bucsics, P. Vella Bonanno, F. Arickx, A. Bybau, T. Bochenek, M. van der Casteele, E. Digene, J. Furst, K. Garuoliene, M. van der Graff, J. Gulbinovic, A. Haycox, J. Jones, R. Joppi, O. Laius, I. Langner, A. Martin, V. Marković Peković, L. McCullagh, E. Magnusson, E. Nilsen, G. Selke, C. Sermet, S. Simoens, R. Sauremann, A. Schuurman, R. Ramos, V. Vlahović-Palčevski, C. Zara, B. Godman, Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways, Frontiers in Pharmacology, Vol. 7, pp. 1 - 9, Sep, 2016

• Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation (2017-08)

  P. Vella Bonanno, M. Ermisch, B. Godman, A. Martin, J. Van Den Bergh, L. Bezmelnitsyna, A. Bucsics, F. Arickx, A. Bybau, T. Bochenek, M. van der Casteele, E. Diogene, I. Eriksson, J. Furst, M. Gad, I. Greičiute-Kuprijanov, M. van der Graff, J. Gulbinovic, J. Jones, R. Joppi, M. Kalaba, O. Laius, I. Langner, I. Mardare, V. Marković Peković, E. Magnusson, O. Melien, D. Meshkov, G. Petrova, G. Selke, C. Sermet, S. Simoens, A. Schuurman, R. Ramos, J. Rodrigues, C. Zara, E. Zebedin-Brandl, A. Haycox, Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation, Frontiers in Pharmacology, Vol. 8, pp. 1 - 13, Aug, 2017

• Systematic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries (2018-01)

  T. Bochenek, V. Abilova, A. Alkan, B. Asanin, I. Beriain, Z. Besovic, P. Vella Bonanno, A. Bucsics, M. Davidescu, E. de Weerdt, N. Duborija-Kovacevic, J. Furst, M. Gaga, E. Gailite, J. Gulbinovic, E. Gurpinar, B. Hanko, V. Hargaden, T. Hotvedt, I. Hoxha, I. Huys, A. Inotai, A. Jakupi, H. Jenzer, R. Joppi, O. Laius, M. Lenormand, D. Makridaki, A. Malaj, K. Margus, V. Marković Peković, N. Miljkovic, J. de Miranda, S. Primozic, D. Rajinac, D. schwartz, R. Sebesta, S. Simoens, J. Slaby, L. Sović-Brkičić, T. Tesar, L. Tzirnis, E. Warminska, B. Godman, Systematic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries, Frontiers in Pharmacology, Vol. 8, No. article 942, pp. 1 - 23, Jan, 2018

• Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018-12)

  B. Godman, A. Bucsics, P. Vella Bonanno, W. Oortwijn, C. Rothe, A. Ferrario, S. Bosselli, A. Hill, A. Martin, S. Simoens, A. Kurdi, M. Gad, J. Gulbinovic, A. Timoney, T. Bochenek, A. Salem, I. Hoxha, R. Sauermann, A. Massele, A. Guerra Junior, G. Petrova, Z. Mitkova, G. Achniotou, O. Laius, C. Sermet, G. Selke, V. Kourafalos, J. Yfantopoulos, E. Magnusson, R. Joppi, M. Oluka, H. Kwon, A. Jakupi, F. Kalemeera, J. Fadare, O. Melien, M. Pomorski, M. Wladysiuk, V. Marković Peković, I. Mardare, D. Meshkov, T. Novakovic, J. Furst, D. Tomek, C. Zara, E. diogene, J. Meyer, R. Malmstrom, B. Wettermark, Z. Matsebula, S. Campbell, A. Haycox, Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets, Frontiers in public health, Vol. 6, No. Article 328, pp. 1 - 21, Dec, 2018

• Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA (2019-02)

  P. Vella Bonanno, A. Bucsics, S. Simoens, A. Martin, W. Oortwijn, J. Gulbinovic, C. Rothe, A. Timoney, A. Ferrario, M. Gad, A. Salem, I. Hoxha, R. Sauremann, M. Kamusheva, M. Dimitrova, G. Petrova, O. Laius, G. Selke, V. Kourafalos, J. Yfantopoulos, E. Magnusson, R. Joppi, A. Jakupi, T. Bochenek, M. Wladysiuk, C. Furtado, V. Marković Peković, I. Mardare, D. Meshkov, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, A. Haycox, S. Campbell, B. Godman, Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 19, No. 3, pp. 251 - 261, Feb, 2019

• Pricing of oral generic cancer medicines in 25 European countries; findings and implications (2019-02)

  B. Godman, A. Hill, S. Simoens, A. Kurdi, J. Gulbinovic, A. Margus, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Hoxha, C. Rodrigues, C. Hierlander, A. Malaj, R. Sauremann, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, G. Selke, J. Yfantopoulos, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. Valk, C. Hagen, A. Ringerud, R. Plisko, M. Wladysiuk, V. Marković Peković, N. Grubiša, T. Ponorac, I. Mardare, T. Novakovic, M. Parker, J. Fraeyman, D. Tomek, M. Obach Cortadellas, C. Zara, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, A. Heycox, Pricing of oral generic cancer medicines in 25 European countries; findings and implications, Generics and Biosimilars Initiative Journal, Vol. 8, No. 2, pp. 49 - 70, Feb, 2019

• The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures (2021-01)

  E. Moorkens, B. Godman, I. Huys, I. Hoxha, A. Malaj, S. Keuerleber, S. Stockinger, S. Mortenhuber, M. Dimitrova, K. Tachkov, L. Vlahović-Palčevski, V. Vlahović-Palčevski, G. Achniotou, J. Slaby, L. Popelkova, K. Kohoutova, D. Bartels, O. Laius, J. Martikainen, G. Selke, V. Kourafalos, E. Magnusson, R. Einarsdottir, R. Adams, R. Joppi, E. Allocati, A. Jakupi, A. Viksna, I. Greičiute-Kuprijanov, P. Vella Bonanno, V. Suttorp, O. Melien, R. Plisko, I. Mardare, D. Meshkov, T. Novakovic, J. Furst, C. Zara, V. Marković Peković, N. Grubiša, G. Befrits, R. Puckett, A. Vulto, The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures, Frontiers in Pharmacology, pp. 1 - 17, Jan, 2021

• Variation in the prices of oncology medicines across Europe and the implications for the future (2021-02)

  B. Godman, S. Simoens, A. Kurdi, G. Selke, J. Yfantopoulos, A. hill, J. Gulbinovic, A. Martin, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Selke Krulichova, E. Allocati, I. Hoxha, A. Malaj, C. Hierlander, A. Nachtnebel, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, R. Plisko, M. Wladysiuk, V. Marković Peković, I. Mardare, T. Novakovic, M. Parker, J. Furst, D. Tomek, K. Banasova, M. Obach Cortadellas, C. Zara, C. Pontes, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, D. Wong-Rieger, S. Campbell, R. Hill, Variation in the prices of oncology medicines across Europe and the implications for the future, Generics and Biosimilars Initiative Journal, Vol. 10, No. 2, pp. 72 - 82, Feb, 2021

• Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021-03)

  B. Godman, A. Hill, S. Simoens, G. Selke, I. Selke Krulichova, C. Zampirolli, A. Martin, W. Oortwijn, A. Timoney, L. Gustafsson, L. Vončina, H. Kwon, J. Gulbinovic, D. Gotham, J. Wale, W. da Silva, T. Bochenek, A. Kurdi, E. Allocati, O. Ogunleye, J. Meyer, I. Hoxha, A. Malaj, C. Hierlander, R. Sauremann, W. Hamelinck, G. Petrova, O. Laius, I. Langner, J. Yfantopoulos, R. Joppi, A. Jakupi, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, M. Wladysiuk, V. Marković Peković, I. Mardare, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, C. Pontes, S. McTaggart, T. Laba, O. Melien, D. Wong-Rieger, S. Bae, R. Hill, Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 21, No. 4, pp. 527 - 540, Mar, 2021

• Systemic Solutions, Legislative And Organizational Frameworks Aimed To Prevent Or Mitigate Drug Shortages In European Countries (2016-11)

  T. Bochenek, B. Godman, A. Bucsics, E. de Weerdt, J. Furst, E. Gailite, T. Hotvedt, I. Huys, A. Inotai, R. Joppi, A. Malaj, K. Margus, V. Marković Peković, S. Simoens, J. Slaby, L. Sović-Brkičić, E. Gurpinar, P. Vella Bonanno, E. Warminska, A. Pilc, Systemic Solutions, Legislative And Organizational Frameworks Aimed To Prevent Or Mitigate Drug Shortages In European Countries, Value in Health, Voulme 19, Issue 7, pp. A445 - A445, Nov, 2016